Physician profile
Justin C Greiwe
NPI 1942444807
$1,044,391.26
in general payments reported to CMS, 2019-2025
54 companies · $274K in 2025
The $274K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $30K · 2021: $113K · 2022: $170K · 2023: $191K · 2024: $233K · 2025: $274K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $456K · Consulting Fee: $161K · Travel and Lodging: $52K · Food and Beverage: $26K · Grant: $3,000 · Education: $54.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $456,207.60 |
| Consulting Fee | $161,132.42 |
| Travel and Lodging | $52,135.20 |
| Food and Beverage | $26,043.27 |
| Grant | $3,000.00 |
| Education | $54.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $509,190.44 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $226,773.66 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $81,701.95 | 2019-2025 | Dupixent |
| Abbvie INC. | $53,420.10 | 2022-2025 | |
| Genentech USA, INC. | $52,327.86 | 2019-2025 | Xolair |
| Dermavant Sciences, INC. | $31,529.72 | 2023-2024 | Tapinarof, Vtama |
| Incyte Corporation | $17,840.84 | 2022-2025 | Opzelura |
| Amgen INC. | $12,261.46 | 2020-2025 | Tezspire, Actimmune |
| Glaxosmithkline, LLC. | $11,159.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Organon LLC | $9,433.18 | 2024-2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $9,199.42 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $7,750.63 | 2023-2025 | Dupixent |
| Alk-Abello, INC | $4,330.85 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Aimmune Therapeutics, INC. | $4,010.76 | 2020-2021 | |
| Genentech, INC. | $3,116.27 | 2019-2023 | Xolair |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $2,254.22 | 2025 | |
| Csl Behring | $1,478.04 | 2019-2025 | Haegarda, Hizentra, Privigen |
| Takeda Pharmaceuticals U.S.A., INC. | $1,123.65 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Pfizer INC. | $753.35 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $701.04 | 2021-2025 | Orladeyo |
| Covis Pharma Gmbh | $556.46 | 2019-2023 | |
| Grifols USA, LLC | $477.11 | 2019-2024 | Prolastin-C Liquid |
| Kaleo, INC. | $356.63 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $333.62 | 2019-2025 | |
| Pharming Healthcare, INC. | $297.31 | 2019-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $291.89 | 2019-2023 | Ajovy, Airduo Digihaler |
| Blueprint Medicines Corporation | $249.40 | 2022-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $234.78 | 2019-2020 | |
| Octapharma USA, INC. | $152.46 | 2019-2023 | Cutaquig |
| Shire North American Group INC | $131.38 | 2019 | |
| Adma Biomanufacturing LLC | $116.51 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.25 | 2020-2023 | Spiriva Respimat |
| Bio Products Laboratory USA, INC. | $88.62 | 2021-2022 | |
| Leo Pharma INC. | $53.73 | 2022-2023 | Adbry |
| Hikma Pharmaceuticals USA | $50.61 | 2022-2024 | Ryaltris |
| Mylan Specialty L.P. | $46.50 | 2023-2024 | Yupelri |
| Horizon Therapeutics Plc | $44.58 | 2019-2023 | Actimmune |
| Ars Pharmaceuticals Operations, INC. | $41.54 | 2025 | Neffy |
| Hospira, INC. | $40.64 | 2024 | |
| Gc Biopharma USA, INC. | $37.71 | 2024-2025 | Alyglo, Alyglo |
| Electromed, INC. | $29.63 | 2021-2022 | |
| Tersera Therapeutics LLC | $28.70 | 2024 | Quzyttir |
| Galderma Laboratories, L.P. | $27.94 | 2025 | Nemluvio |
| Lilly USA, LLC | $27.78 | 2024 | Ebglyss |
| Greer Laboratories, INC. | $26.31 | 2025 | Oralair |
| Circassia INC. | $24.25 | 2023 | Niox |
| Verona Pharma, INC. | $24.24 | 2025 | Ohtuvayre |
| Phadia US INC. | $23.17 | 2023 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $23.00 | 2021 | |
| Azurity Pharmaceuticals, INC. | $22.63 | 2025 | Alvesco |
| Biocryst Pharmaceuticals, INC. | $18.86 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.83 | 2021 | |
| Merck Sharp & Dohme LLC | $15.44 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Greiwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.